Surf Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Surf Bio, Inc. - overview
Established
2021
Location
Palo Alto, CA, US
Primary Industry
Biotechnology
About
Founded in 2021 and based in California, US, Surf Bio, Inc. is a company that provides therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other diseases. In March 2022, Surf Bio, Inc. raised USD 16 million in Seed funding co-led by Breakout Labs and Perceptive Advisors.
As of 2022, Bryan Mazlish is the CEO of the company. The company develops therapeutic solutions for diabetes, oncology, infectious illnesses, gene therapy, and other therapeutic areas using a surfactant. The firm is developing ultra-rapid insulin for diabetes treatment and is collaborating with pharmaceutical and biotech businesses to incorporate the stabilizing platform into its products. The organization plans to use the March 2022 funds for a polymer-based drug delivery platform and develop ultra-rapid insulin to treat diabetes.
Current Investors
Gates Foundation Trust
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.surf.bio
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.